Date/Time: Tuesday, June 2, 2020 at 8 PM EST

 webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.

Highlights from ASCO CAR T-cell abstracts and presentations

Associate Professor Section Chief, Indolent Lymphoma Section Chief, New Drug Development Department Lymphoma/Myeloma UT MD Anderson Cancer Center 

Associate Professor, Internal Medicine Medical Director, Lymphoma Research Division of Oncology & Hematology University of Nebraska Medical Center

Professor of Medicine Division of Hematologic Malignancies and Cellular Therapy Duke University School of Medicine

News

® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses. 

CAR T-cell Therapy

 CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment. 

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, June 2, 2020 at 8 PM EST.

Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: What's on the Horizon for CAR T-Cell Therapies